Study of dabigatran etexilate polymorphs for improved manufacturing processability

被引:0
|
作者
Datir, Satyajit R. [1 ]
Bele, Mrudula H. [1 ]
机构
[1] Maratha Vidya Prasarak Samajs Coll Pharm, Nasik 422002, Maharashtra, India
关键词
A1; Polymorph; Dabigatran etexilate; Hydrate; A2; Flow property; Tensile strength; Recrystallization; CRYSTAL HABIT MODIFICATIONS; POWDER; COMPRESSIBILITY;
D O I
10.1016/j.jcrysgro.2022.127047
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
In the present work on anhydrous form-I and tetrahydrate form of Dabigatran etexilate a comparative study was done to seek a polymorph which will perform better in downstream processing and dissolution. Anhydrous form I of Dabigatran etexilate used in this study is having a needle shape. Tetrahydrate form was recrystallized from the anhydrous form I by solvent recrystallization using a slow evaporation method with acetone at NMT 25 degrees C, 2-8 degrees C, and -20 degrees C. The crystal shape of recrystallized tetrahydrate form was tabular. Scanning electron microscopy (SEM) was used to confirm the shape of crystals. Powder X-ray Diffraction (PXRD), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), and Fourier Transform Infrared Spectroscopy (FTIR) analysis confirmed polymorphic change. Flow characterization indicates that tetrahydrate has better bulk density, tapped density, Hausner ratio, and Cars index than anhydrous form I. Kawakita analysis shows that tetrahydrate has better compactibility and lesser cohesive nature than anhydrous form I. Heckel plots indicates tendency of tetrahydrate form to undergo plastic deformation linearly as pressure increases compared to anhydrous form I. The tensile strength of tetrahydrate is better than anhydrous form I and it also have a lesser tendency for capping and lamination at higher compression pressure. A dissolution study in USP dissolution media for dabigatran etexilate showed that tetrahydrate has a higher dissolution rate than anhydrous form I which is also backed by higher solubility. Overall, the tetrahydrate form can be preferred over the anhydrous form I during polymorph selection.
引用
收藏
页数:7
相关论文
共 50 条
  • [2] Dabigatran etexilate
    不详
    AUSTRALIAN PRESCRIBER, 2009, 32 (02) : 51 - 52
  • [3] Dabigatran etexilate
    Eriksson, Bengt I.
    Smith, Helen
    Yasothan, Uma
    Kirkpatrick, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (07) : 557 - 558
  • [4] Dabigatran etexilate
    Sanford, Mark
    Plosker, Greg L.
    DRUGS, 2008, 68 (12) : 1699 - 1709
  • [6] Dabigatran etexilate
    Bengt I. Eriksson
    Helen Smith
    Uma Yasothan
    Peter Kirkpatrick
    Nature Reviews Drug Discovery, 2008, 7 : 557 - 558
  • [7] Dabigatran Etexilate
    Mark Sanford
    Greg L. Plosker
    Drugs, 2008, 68 : 1699 - 1709
  • [8] Dabigatran etexilate
    Dubois, Eline A.
    Cohen, Adam F.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 14 - 15
  • [9] Dabigatran etexilate and itraconazole
    Legeay, Samuel
    Faure, Sebastien
    ACTUALITES PHARMACEUTIQUES, 2022, 61 (616): : 15 - 17
  • [10] UTILIZATION STUDY OF DABIGATRAN ETEXILATE IN HOSPITALIZED PATIENTS
    Lopez Isabel, Cuesta
    Silveira Eva, Delgado
    Vicedo Teresa, Bermejo
    Gonzalez Juana, Benedi
    ATENCION FARMACEUTICA, 2012, 14 (03): : 174 - 178